Daniel Chevallard
Director of Finance/CFO chez Viracta Subsidiary, Inc.
Fortune : 104 352 $ au 31/03/2024
Postes actifs de Daniel Chevallard
Sociétés | Poste | Début | Fin |
---|---|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Director of Finance/CFO | 01/07/2019 | - |
Historique de carrière de Daniel Chevallard
Anciens postes connus de Daniel Chevallard
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIRACTA THERAPEUTICS, INC. | Chief Operating Officer | 03/03/2021 | 20/03/2024 |
Director of Finance/CFO | 01/07/2019 | 20/03/2024 | |
Corporate Secretary | 01/07/2019 | 20/03/2024 | |
Treasurer | 01/07/2019 | 20/03/2024 | |
REGULUS THERAPEUTICS INC. | Comptroller/Controller/Auditor | 01/12/2012 | 26/07/2019 |
Director of Finance/CFO | 04/05/2017 | 26/07/2019 | |
Corporate Officer/Principal | 01/05/2013 | 04/05/2017 | |
VIRACTA THERAPEUTICS, INC. | Director of Finance/CFO | 24/02/2021 | - |
Corporate Secretary | 24/02/2021 | - | |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Comptroller/Controller/Auditor | - | - |
Director of Finance/CFO | - | - |
Formation de Daniel Chevallard
University of San Diego | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Opérationnelle
Director of Finance/CFO | 6 |
Comptroller/Controller/Auditor | 2 |
Corporate Secretary | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
REGULUS THERAPEUTICS INC. | Health Technology |
VIRACTA THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
- Bourse
- Insiders
- Daniel Chevallard
- Expérience